ReviewSurgery today2026
Adjuvant treatment for esophageal cancer.
Review in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophagectomy is the standard treatment for resectable esophageal cancer (EC). Recently, the prognosis of EC has gradually improved owing to the introduction of minimally invasive surgery, enhanced postoperative recovery, and perioperative nutritional treatment. However, more than half of the patients who undergo esophagectomy experience recurrence, even after curative esophagectomy. Once EC recurs, the prognosis for patients with recurrent EC is limited. Tumor cell metastasis is the most common cause of recurrence. Micrometastatic cells grow in unresectable regions after curative esophagectomy. Therefore, control of micrometastasis is necessary to prevent the recurrence of EC in the perioperative period. Perioperative adjuvant treatment has been introduced for various malignancies, including EC, to prevent recurrence due to micrometastasis. Since 1990, evidence has emerged regarding postoperative adjuvant treatment, preoperative adjuvant treatment, and perioperative adjuvant treatment for resectable EC. To optimize adjuvant treatment for resectable esophageal cancer, it is necessary to understand the characteristics of each approach before the introduction of adjuvant treatment for resectable esophageal cancer. This review summarizes the background, current status, and future perspectives of adjuvant therapy for resectable esophageal cancer.
Indexed as
Identifiers
41284061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.